Lupin Limited · NSE:LUPIN
Lupin — Q4 FY26 Earnings Presentation
21 slides from Lupin's earnings presentation, May 7, 2026
Slide 1: Exchange filing cover letter - Investor Presentation Q4 FY26
May 07, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, P. J. Towers, Dalal Street, Bandra Kurla Complex, Mumbai Samachar Marg, Bandra (East), Mumbai - 400 001 Mumbai - 400 051 Symbol: LUPIN Scrip Code: Equity - 500257 Subject: Investor Presentation - Q4 FY26 Dear Sir/Madam
Slide 2: Investor Presentation Q4 FY26
Investor Presentation Q4 FY26 May 07, 2026
Slide 3: Safe Harbor Statement
Safe Harbor Statement Materials and information provided during this presentation may contain forward looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ
Slide 4: Q4 FY26 Performance
Q4 FY26 Performance
Slide 5: Q4 FY26 - Key Growth Metrics
Q4 FY26 - Key Growth Metrics Continued Strong Operating Performance Key Metrics Business Performance Values in INR unless indicated otherwise 73,919 mn Sales India APAC 33% YoY 19,082 mn | 12% YoY 3,515 mn | 9% YoY LATAM 3,144 mn | 75% YoY 21,711 mn EBITDA1 29.4% North America 68% YoY Margin 35,145
Slide 6: Q4 FY26 - Key Developments
Q4 FY26 - Key Developments Strong Revenue Growth with Healthy EBITDA Margins Financials Key Launches / Approvals Sales* and EBITDA margin Trajectory US FDA Dapagliflozin Tabs Launched Sugammadex Inj Tentative (gFarxiga®) In US (gBridion®) 80,000 73,919 approval 68,314 71,005 70,000 37.0% 61,638 60,0
Slide 7: Q4 FY26: Financial Snapshot
Q4 FY26: Financial Snapshot Sales Mix Key Financials INR mn Revenue (In INR mn and %) United India, States, Q4 FY26 Q4FY25 Q3 FY26 33,9871 19,082 46% 26% Sales 73,919 55,622 71,005 API, 2,491 3% EBITDA3 21,711 12,921 22,095 Emerging Other Developed Markets2, Net Income4 14,604 7,725 11,756 Markets3,
Slide 8: India: Focus on outperforming market growth
India: Focus on outperforming market growth Brief Overview India business grew 11.5%1 YoY Brief Overview Leveraging Chronic Leadership India Sales (INR mn) #2 #3 #3 Rank Rank Rank 20,894 20,777 20,387 19,082 Respiratory2 Cardiac2 Diabetes Care2 17,113 • Chronic growth 14.4% in FY26 vs IPM growth of
Slide 9: India: Amplifying our Core
India: Amplifying our Core IRF poised to outperform IPM by 1.2-1.3x with key drivers in place Enabling end to end healthcare ecosystem and access for the patient Enhancing penetration and reach CHC Portfolio catering to GI, VMS, • Maximizing Chronic focus with ~70% share by FY31 Cough/cold therapies
Slide 10: United States: Continued momentum on Key Launches
United States: Continued momentum on Key Launches BriefLeadership: Overview 4.8% Gx TRx volume Consistent Sales trajectory3 Continued momentum led by Brief Overview share in U.S.1 investments in complex Gx & 505(b)(2) Sales in US$ Mn 48% YoY 6% QoQ • Filed 10+ ANDAs in FY26 including two #3 #1 505(b
Slide 11: Innovation and Quality
Innovation and Quality R&D pivoting towards complex generics and biosimilars Achieve Best-in-Class Quality Substantial Capabilities to become CGx powerhouse Recent Track Record Successful outcomes in last 12 months • Inhalation: Global presence with end-to-end capabilities of MDIs, DPIs, Soft-Mist I
Slide 12: Key Financial Metrics: Quarterly Trend
Key Financial Metrics: Quarterly Trend R&D (INR mn) Capex (INR mn) Net Debt to Equity 6,500 5,898 15.0%4,500 15.0% 5,430 5,222 5,352 5,500 4,975 13.0%4,000 3,474 13.0% 11.0% 3,500 3,052 0.35 11.0% 4,500 3,000 0.25 9.0% 9.0% 3,500 9.8% 2,500 2,086 7.0% 2,007 7.0% 0.15 2,500 8.1% 7.6% 7.5% 8.0% 2,000
Slide 13: P&L Highlights Q4 FY26
P&L Highlights Q4 FY26 Particulars Q4’FY26 % of Sales Q4’FY25 % of Sales YoY Growth Q3’FY26 % of Sales QoQ Growth Net Sales 73,919 100.00% 55,622 100.00% 32.9% 71,005 100.00% 4.1% Other operating 828 1.1% 1,049 1.9% (21.1%) 670 0.9% 23.3% income Total revenue 74,747 101.1% 56,671 101.9% 31.9% 71,675
Slide 14: P&L Highlights - FY26
P&L Highlights - FY26 Particulars FY26 % of Sales FY25 % of Sales YoY Growth Net Sales 274,875 100.0% 221,921 100.0% 23.9% Other operating income 4,705 1.7% 5,158 2.3% (8.8%) Total revenue 279,580 101.7% 227,079 102.3% 23.1% Gross Profit (excl. other 201,610 73.3% 153,499 69.2% 31.3% operating incom
Slide 15: Lupin at a Glance
Lupin at a Glance
Slide 16: Lupin Today
Lupin Today Global Presence Local Leadership Geographically Diverse Growing Sustainability Largest In the US (by India United States 3rd 81,140 116,783 14th $3.2 Bn prescriptions2) 30% 42% India Pharma Market Rank (by 8th sales3) Largest Generic Company (by sales1) Annual sales in FY266 4th Largest
Slide 17: Catalyzing Treatments that transform hope into healing
Catalyzing Treatments that transform hope into healing United States Other Developed India Other Emerging API Markets Markets Driving operating Global reach and scale Substantial scale Evolving portfolio and Delivering above- leverage in Portfolio, positions us as a achieving reliability of pipeline
Slide 18: Lupin's ESG Update
Lupin’s ESG Update Key Highlights Paving a sustainable future for Planet, People and Patients ESG Goal Status FY 2026 Climate 42% GHG Reduction by Change1 ~35% GHG Reduction 2030 45% Recycling Earned our first-ever leadership ‘A’ Carbon emissions reduction target Water 50% Recycling by 2030 rating i
Slide 19: Lupin ESG Framework and ESG Ratings
Lupin ESG Framework and ESG Ratings Our Purpose Planet People Patients We catalyze treatments that transform hope into Catalyzing Planet Action Transforming Our People Healing Patients healing Climate Change Diversity and Inclusion Product Launches and Quality Our ESG Framework Water Employee Volunt
Slide 20: Lupin – Awards and Accolades
Lupin – Awards and Accolades • Lupin placed among the Top 1% of companies in Pharma industry based on S&P Global CSA score for 2025. Earns a spot in Sustainability Yearbook for 3rd time in a row • Lupin Secured Global No. 1 Ranking in the Pharma Sector in S&P Global ESG Ratings and Secured No. 1 in
Slide 21: Thank You
Thank You lupin.com youtube.com/c/LupinGlobal x.com/LupinGlobal Registered Address facebook.com/LupinWorld/ 3rd Floor, Kalpataru Inspire, Off Western Express Phone: +91 22664 02323 linkedIn.com/company/lupin Highway, Santacruz (East), Mumbai - 400055, India Fax: +91 22664 02051